Artur Fedorowski

Artur Fedorowski

Adjunct Professor
Visiting address: Norrbacka S1:02, Karolinska Universitetssjukhuset Solna, 17176 Stockholm
Postal address: K2 Medicin, Solna, K2 Kardio Pernow J, 171 77 Stockholm

About me

  • Name: Artur Fedorowski

    Born: 9th July 1965, Wroclaw, Poland

    Working place: Senior Consultant and Head of Syncope and Dysautonomia Unit; Dept. of Cardiology, Karolinska University Hospital, 176 71 Stockholm (Sweden);

    Academic position: Professor, Dept. of Medicine, Solna, Karolinska Institute, Stockholm, Sweden.

     

    Education:

    • 1984 - 1990 - Wrocław Medical University, Poland (MD, “Cum laude”)
    • 1995 - 1999 - Wroclaw Medical University, Poland: PhD studies; doctoral thesis (June 22, 1999): "Influence of Low - Frequency Electromagnetic Field on the Growth of Morris Hepatoma in Experimental Model in Rats" / in parallel, specialist training in internal medicine and cardiology.
    • 2001-2006 – Sweden specialist training in general medicine (2001-2003), and complementary training in internal medicine (2004-2005), and cardiology (2005-2006).
    • 2007 – 2012 – Dept. of Clinical Sciences, Lund University, Malmö, Sweden; Post-Doc position in cardiovascular medicine.
    • 2013 - Associate Professor, Lund University; Cardiovascular Medicine
    • 2016 – Fellow of the European Society of Cardiology
    • 2023 – Full Professor of Cardiology; Karolinska Institute, Stockholm

    Academic mentorship

    • PhD students: 7 as main supervisor; 6 as co-supervisor (5 PhD projects as main supervisor completed).
    • Post-doc: 2 as main supervisor.

     

    Professional experience

    • Specialist in cardiology, internal and general medicine
    • Senior consultant in cardiology since 2013 (Skåne University Hospital 2013-2021; Karolinska University Hospital 2021- now)
    • Member of the Task Force Group of European Society of Cardiology for Syncope Guidelines (2018)
    • Member of National Institute of Health (USA) Expert Group on Postural Orthostatic Tachycardia Syndrome (2019)
    • Member of European Heart Rhythm Association expert group on dysautonomia and cardioneuroablation (2023-2024).
    • Research areas: syncope, orthostatic hypotension, cardiac arrhythmias, cardiovascular autonomic dysfunction, hypertension, biomarkers, autoimmune cardiovascular diseases, genetics of cardiovascular disease, post-COVID syndrome.

     

    Associate editor: Europace, Autonomic Neuroscience, Scientific Reports, Journal of Clinical Medicine; Frontiers in Neuroscience/ Physiology; Emergency and Internal Medicine.

    Reviewer: approx. 60 medical journals; Lancet, BMJ, Lancet Neurology, Nature Reviews Nephrology/Neurology, JACC, Circulation, European Heart Journal, Hypertension, American Journal of Physiology, Annals of Internal Medicine, JAMA Internal Medicine, Brain, Europace.

     

Research

  • Our research is focused on cardiovascular autonomic dysfunction and various syncope mechanisms, including reflex syncope and autonomic failure. Two major forms of orthostatic intolerance: orthostatic hypotension and POTS, a source of frustration for doctors and their patients, are also in the centre of our scientific interest. Finally, we explore how cardiovascular and autonomic systems interact on cellular, organ and organism levels.

Articles

All other publications

Grants

  • Swedish Heart-Lung Foundation
    1 January 2023 - 31 December 2025
    Background: Almost one third of those affected by post-acute COVID sequelae (PACS) or Long Covid demonstrate clinical signs of postural orthostatic tachycardia syndrome (POTS). The demographics of post-COVID POTS poses a huge burden as the syndrome impacts mainly younger and middle-aged women who are no longer able to work and take care of their families. The cause of POTS remains a mystery and therapy is largely unsatisfactory. Aims: The following hypotheses will be tested: A) Post-COVID POTS is a condition with an autoimmune aetiology directed against major types of cardiovascular(CV) G-protein coupled receptors. B) Post-COVID POTS is a chronic inflammatory condition with significant changes in inflammatory proteins and immunological markers. C) Post-COVID POTS is a condition associated with microvascular dysfunction. D) Post-COVID POTS may share different additional phenotypes such as inappropriate sinus tachycardia and low-blood pressure phenotype, which should be detected and treated appropriately. E) A subset of patients with post-COVID POTS share the same pathophysiological mechanisms as mast cell activation disorders. Work plan: The patients will be recruited 2022-2023 through referrals from a dedicated post-COVID clinic at Karolinska and directly from specialists and primary care plus from external referrals from other administrative regions. As of today, more than 350 patients have been identified and will be included. Patients will be examined by CV autonomic tests, long-term hemodynamic monitoring, cardiac MRI,, endothelial function tests, and immunological (for GPCR-autoantibodies), neuroendocrine (for endothelial dysfunction), less discriminative proteomics (through mass spectrometry) and mast cell activation tests. Based on autonomic, cardiac, endothelial and biochemical tests, the most promising therapeutic targets will be selected for the second stage of project (interventional). This part will be launched first 2023-2024. Significance:Our understanding, diagnostics, and therapy of long-term post-COVID cardiovascular dysautonomia such as POTS, are largely unsatisfactory. It is estimated that one third of Long COVID patients will develop this chronic condition. This project is aimed to answer the questions whether post-COVID POTS and dysautonomia are chronic autoimmune and inflammatory conditions, what are the main mechanisms behind syndrome s debilitating consequences, how to best diagnose it and how to treat it more effectively.
  • Swedish Research Council
    1 December 2021 - 30 November 2025
    We have recently discovered three cardiovascular phenotypes in post covid: Postural orthostatic tachycardia syndrome (POTS), unspecific sinus tachycardia and cardiac microvascular dysfunction. The pathophysiology and optimal treatment strategies for these remain unknown. The overall aim is to characterize several biological aspects of the cardiovascular phenotypes to identify pathophysiological mechanisms (identifying novel therapeutic targets) and to conduct a series proof-of-concept randomized, placebo-controlled, double-blind, clinical trials (RCTs) using available interventions targeting putative mechanisms.Patients will be included from the post covid clinic at Karolinska University Hospital and the study will run 2022-2025. In collaboration with several experts at Karolinska University Hospital and nationally, stress-perfusion cardiac magnetic resonance imaging (microvascular dysfunction), endothelial function studies and advanced assessment of dysautonomias (e.g. POTS) will be performed. Protein- and lipid biomarkers (proteomics and lipidomics
    mass spectrometry) will be analyzed. In parallel, proof-of-concept RCT using drugs with documented effect in similar diseases will be conducted. These RCTs will then serve as a foundation for future clinical studies targeting discovered mechanisms. The result from this study may lead to rapid implementation of evidence-based treatment and discoveries of novel therapeutic targets in a large and underserved patient population.
  • Swedish Heart-Lung Foundation
    1 January 2021 - 31 December 2021
  • Swedish Heart-Lung Foundation
    1 January 2020 - 31 December 2021
  • Swedish Heart-Lung Foundation
    1 January 2020 - 31 December 2020
  • Swedish Heart-Lung Foundation
    1 January 2019 - 31 December 2019

News from KI

Events from KI